SynuSight, ABLi Therapeutics, and XingImaging Collaborate on Alpha-Synuclein PET Imaging for Parkinson's Trials A strategic partnership among SynuSight Biotech, ABLi Therapeutics, and XingImaging aims to enhance clinical trials of risvodetinib through advanced imaging techniques for Parkinson's disease.

SynuSight, ABLi Therapeutics, and XingImaging Collaborate on Alpha-Synuclein PET Imaging for Parkinson's Trials #United_States #New_Haven #XingImaging #SynuSight #ABLi_Therapeutics

XingImaging and SynuSight Collaborate on Innovative PET Tracer for Parkinson's Research XingImaging has partnered with SynuSight to develop a PET tracer for Parkinson’s disease, supported by a $3.84M grant from The Michael J. Fox Foundation.

XingImaging and SynuSight Collaborate on Innovative PET Tracer for Parkinson's Research #United_States #New_Haven #XingImaging #SynuSight #ParkinsonsDisease